JW THERAP-B (02126.HK): CAR-T Product Added to National Reimbursement List at RMB288,600

On 15 Nov 2026, JW THERAP-B (02126.HK) said its CAR-T product relma-cel joined China's 2026 reimbursement list at RMB288,600 from 1 January 2027.

NewTimeSpace News: On 15 November 2026, JW (Cayman) Therapeutics Co. Ltd (stock code: 2126) published an announcement under Rule 13.09(2)(a) of the Listing Rules and the inside information provisions of Part XIVA of the Securities and Futures Ordinance that its core product, relmacabtagene autoleucel injection (relma-cel), has been formally added to the 2026 edition of the National Reimbursement Drug List, so that from 1 January 2027 eligible patients can obtain basic medical insurance reimbursement as prescribed.

The reimbursement scope covers all three approved indications of the product: large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. The reimbursed price is RMB288,600.

The product is the only chimeric antigen receptor T-cell (CAR-T) therapy added to the national list in this round, which should lower the payment threshold for eligible patients and bring the therapy more widely into clinical decision-making. As at 31 October 2026, the longest follow-up in its registrational study had reached eight years, more than 1,200 patients had been treated at over 200 certified treatment centres across China, and its post-marketing real-world study had enrolled 200 patients.

Since commercial launch, the product has achieved a 99% one-time manufacturing success rate and a 100% delivery rate. The Company will continue to optimise manufacturing processes, quality systems and operating efficiency to meet likely growth in demand once reimbursement begins.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.